GLP-1 receptor agonists: which added value when increasing the dose?

Affiliations

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, B-4000 Liège, Belgium; Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines, Liège University, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.

Comment

André J Scheen. Lancet Diabetes Endocrinol. 2021 Sep.

. 2021 Sep;9(9):546-548.

doi: 10.1016/S2213-8587(21)00205-9. Epub 2021 Jul 21.

¹ Division of Diabetes, Nutrition and Metabolic Disorders, Department of Medicine, CHU Liège, B-4000 Liège, Belgium; Division of Clinical Pharmacology, Center for Interdisciplinary Research on Medicines, Liège University, Liège, Belgium. Electronic address: andre.scheen@chu.ulg.ac.be.

No abstract available

Conflict of interest statement

I worked as a clinical investigator in the SCALE and STEP-1 trials with subcutaneous semaglutide.

Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP, Auerbach P, Bajaj HS, Fukushima Y, Lingvay I, Macura S, Søndergaard AL, Tankova TI, Tentolouris N, Buse JB. Frías JP, et al. Lancet Diabetes Endocrinol. 2021 Sep;9(9):563-574. doi: 10.1016/S2213-8587(21)00174-1. Epub 2021 Jul 21. Lancet Diabetes Endocrinol. 2021. PMID: 34293304 Clinical Trial.